drugset / Trial / NCT02677259

Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles

NCT02677259

Phase 2 Unknown 506 enrolled One Fertility
RandomizedParallel-groupOpen-labelTreatment

Summary

Optimizing in vitro fertilization (IVF) success is more important than ever, in light of new public funding of IVF in Ontario, Canada. In patients undergoing IVF using gonadotropin-releasing hormone (GnRH) analogues, the luteal phase appears to be compromised, which may be a result of controlled-ovarian hyperstimulation, significant fluctuations in hormone levels, the impact of the oocyte retrieval process, or direct compromise of the corpus luteum. Progesterone support is definitely necessary during the luteal phase to facilitate implantation but whether estrogen supplementation is also needed remains unclear. The present study aims to determine whether estradiol support during the luteal phase improves clinical pregnancy rate in patients undergoing IVF.

Timeline

Start
2016-05
Primary completion
2018-06
Completion
2018-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 17-beta estradiol Unknown 3 mg Oral
Background Progesterone Other / unclassified 200 mg Other

Indications

No indication recorded.